TimesSquare Capital Management LLC reduced its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 6.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,710,926 shares of the company's stock after selling 116,769 shares during the period. TimesSquare Capital Management LLC owned approximately 1.70% of Day One Biopharmaceuticals worth $21,677,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of DAWN. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after buying an additional 1,002 shares in the last quarter. Quest Partners LLC increased its stake in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after buying an additional 7,668 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $174,000. Finally, XTX Topco Ltd purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $178,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have commented on DAWN. Bank of America cut their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. TD Cowen upgraded Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Needham & Company LLC restated a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $35.71.
Get Our Latest Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Price Performance
DAWN traded up $0.15 during trading hours on Friday, reaching $12.38. The company's stock had a trading volume of 427,462 shares, compared to its average volume of 970,589. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $18.07. The stock has a market cap of $1.25 billion, a PE ratio of -12.02 and a beta of -1.46. The business's 50-day moving average is $12.38 and its 200-day moving average is $13.48.
Insider Buying and Selling at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now owns 1,034,015 shares of the company's stock, valued at $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is owned by corporate insiders.
About Day One Biopharmaceuticals
(
Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
